SK ChemicalsLtd Balance Sheet Health
Financial Health criteria checks 5/6
SK ChemicalsLtd has a total shareholder equity of ₩2,666.6B and total debt of ₩1,350.9B, which brings its debt-to-equity ratio to 50.7%. Its total assets and total liabilities are ₩4,377.1B and ₩1,710.6B respectively. SK ChemicalsLtd's EBIT is ₩62.4B making its interest coverage ratio 4.7. It has cash and short-term investments of ₩1,615.4B.
Key information
50.7%
Debt to equity ratio
₩1.35t
Debt
Interest coverage ratio | 4.7x |
Cash | ₩1.62t |
Equity | ₩2.67t |
Total liabilities | ₩1.71t |
Total assets | ₩4.38t |
Recent financial health updates
No updates
Recent updates
We Think That There Are More Issues For SK ChemicalsLtd (KRX:285130) Than Just Sluggish Earnings
Mar 22There Is A Reason SK Chemicals Co.,Ltd's (KRX:285130) Price Is Undemanding
Mar 15We Think SK ChemicalsLtd's (KRX:285130) Robust Earnings Are Conservative
Mar 29Should You Think About Buying SK Chemicals Co.,Ltd. (KRX:285130) Now?
Mar 24Imagine Holding SK ChemicalsLtd (KRX:285130) Shares While The Price Zoomed 499% Higher
Mar 02An Intrinsic Calculation For SK Chemicals Co.,Ltd. (KRX:285130) Suggests It's 21% Undervalued
Feb 08SK Chemicals Co.,Ltd. (KRX:285130) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Jan 20What Type Of Shareholders Own The Most Number of SK Chemicals Co.,Ltd. (KRX:285130) Shares?
Dec 30When Should You Buy SK Chemicals Co.,Ltd. (KRX:285130)?
Dec 09Did You Miss SK ChemicalsLtd's (KRX:285130) Whopping 729% Share Price Gain?
Nov 19Financial Position Analysis
Short Term Liabilities: A285130's short term assets (₩2,261.1B) exceed its short term liabilities (₩979.1B).
Long Term Liabilities: A285130's short term assets (₩2,261.1B) exceed its long term liabilities (₩731.5B).
Debt to Equity History and Analysis
Debt Level: A285130 has more cash than its total debt.
Reducing Debt: A285130's debt to equity ratio has reduced from 141.3% to 50.7% over the past 5 years.
Debt Coverage: A285130's debt is not well covered by operating cash flow (13%).
Interest Coverage: A285130's interest payments on its debt are well covered by EBIT (4.7x coverage).